<p>道格拉斯·莱恩与合伙公司在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第三季度将其在艾朗克动物健康公司（NYSE:ELAN - 免费报告）的股份减少了 1.9%。该基金在此期间出售了 68,407 股后，持有 3,444,268 股该公司的股票。道格拉斯·莱恩与合伙公司在其最近向证券交易委员会（SEC）提交的文件中拥有艾朗克动物健康 0.69% 的股份，价值 69,368,000 美元。</p>
<p>获取 <strong>艾朗克动物健康</strong> 的提醒：</p>
<ul>
<li>看涨还是看跌？评估动物健康护理股票</li>
</ul>
<p>其他对冲基金和机构投资者最近也调整了对该公司的持股。第一地平线顾问公司在第二季度将其在艾朗克动物健康的持股增加了 184.3%。第一地平线顾问公司现在拥有 3,724 股该公司的股票，价值 53,000 美元，此前在上个季度增持了 2,414 股。凯通国际资产管理有限公司在第二季度将其在艾朗克动物健康的持股增加了 261.6%。凯通国际资产管理有限公司现在拥有 4,039 股该公司的股票，价值 58,000 美元，此前在上个季度增持了 2,922 股。基诺斯财富管理公司在第二季度将其在艾朗克动物健康的持股增加了 53.7%。基诺斯财富管理公司现在拥有 5,954 股该公司的股票，价值 85,000 美元，此前在上个季度增持了 2,080 股。EverSource 财富顾问公司在第二季度将其在艾朗克动物健康的持股增加了 26.4%。EverSource 财富顾问公司现在拥有 6,379 股该公司的股票，价值 91,000 美元，此前在上个季度增持了 1,332 股。最后，平行顾问公司在第二季度将其在艾朗克动物健康的持股增加了 66.6%。平行顾问公司现在拥有 6,432 股该公司的股票，价值 92,000 美元，此前在上个季度增持了 2,572 股。机构投资者持有该公司 97.48% 的股票。</p>
<h2>华尔街分析师观点</h2>
<p>多位分析师对该公司发布了报告。巴克莱在 12 月 9 日的研究报告中开始覆盖艾朗克动物健康。他们对该股票给予了 “增持” 评级，并设定了 30.00 美元的目标价。摩根士丹利在周四将艾朗克动物健康的目标价从 18.00 美元上调至 22.00 美元，并给予该股票 “持平” 评级。扎克斯研究在 11 月 6 日的研究报告中将艾朗克动物健康的评级从 “强力买入” 下调至 “持有”。瑞银集团在 11 月 6 日的研究报告中将艾朗克动物健康的目标价从 25.00 美元上调至 27.00 美元，并给予该股票 “买入” 评级。最后，阿古斯在 11 月 19 日的研究报告中将艾朗克动物健康的评级从 “持有” 上调至 “买入”，并设定了 25.00 美元的目标价。两位投资分析师对该股票给予了强力买入评级，七位给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 23.78 美元。</p>
<ul>
<li>Zoetis 宣布新股息，暗示被低估</li>
</ul>
<p><strong>阅读我们关于艾朗克动物健康的最新研究报告</strong></p>
<h2>艾朗克动物健康股票表现</h2>
<p>艾朗克动物健康的股票在周五开盘价为 22.28 美元。艾朗克动物健康公司的一年最低价为 8.02 美元，一年最高价为 23.70 美元。该公司的 50 日移动平均线为 21.92 美元，200 日移动平均线为 18.37 美元。该公司的市值为 110.7 亿美元，市盈率为 371.40，市盈增长比率为 3.41，贝塔值为 1.86。该公司的债务与股本比率为 0.59，流动比率为 2.40，速动比率为 1.23。</p>
<ul>
<li>2 只具有重大上涨潜力的逆向股票推荐</li>
</ul>
<p>艾朗克动物健康（NYSE:ELAN - 获取免费报告）在 11 月 5 日星期三发布了季度财报。该公司报告每股收益为 0.19 美元，超出市场共识预期的 0.13 美元，超出幅度为 0.06 美元。艾朗克动物健康的股本回报率为 7.41%，净利润率为 0.78%。该公司在本季度的收入为 11.4 亿美元，而市场共识预期为 10.9 亿美元。在去年同期，该公司每股收益为 0.13 美元。该公司本季度的收入同比增长 10.4%。艾朗克动物健康已将其 2025 财年的指导目标设定为每股收益 0.910-0.940 美元，并将其 2025 年第四季度的指导目标设定为每股收益 0.090-0.120 美元。研究分析师预测艾朗克动物健康公司本年度将发布 0.91 美元的每股收益。</p>
<h2>艾朗克动物健康的内部活动</h2>
<p>在其他 Elanco Animal Health 的新闻中，董事 Lawrence Erik Kurzius 于 12 月 12 日（星期五）购买了公司 10,000 股股票。每股的平均购买成本为 21.30 美元，总交易额为 213,000.00 美元。完成购买后，该董事在公司拥有 131,773 股股票，估值约为 2,806,764.90 美元。这笔交易代表了他们持股比例的 8.21% 的增长。该交易已在向 SEC 提交的文件中披露，可以通过此链接访问。此外，内部人士 Rajeev A. Modi 于 12 月 11 日（星期四）购买了公司 4,500 股股票。每股的平均购买成本为 21.33 美元，总交易额为 95,985.00 美元。完成收购后，该内部人士拥有 123,082 股公司的股票，估值为 2,625,339.06 美元。这笔交易代表了他们持股比例的 3.79% 的增长。有关此次购买的更多细节可在官方 SEC 披露中找到。在过去的九十天里，内部人士共购买了 43,450 股公司股票，价值为 937,883 美元。公司内部人士持有公司股票的 0.89%。</p>
<h2>Elanco Animal Health 公司简介</h2>
<p>（免费报告）</p>
<p>Elanco Animal Health Inc 是一家全球领先的动物健康公司，致力于改善食品和伴侣动物的福祉。该公司开发、生产和销售一系列产品，包括寄生虫药、疫苗、抗生素和饲料添加剂，旨在预防和治疗家畜和宠物的疾病。Elanco 的产品组合涵盖了食品生产动物（如牛、猪、家禽和水产养殖）和伴侣动物，提供支持寄生虫控制、疼痛管理和传染病预防的产品。</p>
<p>Elanco 最初成立于 20 世纪中期，作为礼来公司（Eli Lilly and Company）的动物健康部门，并于 2018 年分拆为一家独立的上市公司。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Elanco Animal Health</li>
<li>技术指标如何帮助你找到被低估的股票</li>
<li>这三家银行在年末上涨，但这种趋势会持续吗？</li>
<li>股票中的死亡交叉是什么？</li>
<li>这三只飙升的股票刚刚获得标准普尔 500 的最终认可</li>
<li>三只 REIT 值得长期持有</li>
<li>这只 ETF 在美联储降息后获得了重大助力</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMQU4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMQU4"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Elanco Animal Health 吗？</h2>
<p>在考虑 Elanco Animal Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Elanco Animal Health 并不在名单上。</p>
<p>虽然 Elanco Animal Health 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ELAN

<p>道格拉斯·莱恩与合伙公司在第三季度将其在 Elanco Animal Health 的持股减少了 1.9%，目前持有 3,444,268 股，价值 6937 万美元。其他投资者则增加了他们的持股。分析师的评级各不相同，平均目标价为 23.78 美元。Elanco 的股票开盘价为 22.28 美元，市值为 110.7 亿美元。最近的财报超出预期，报告每股收益为 0.19 美元，营收为 11.4 亿美元</p>

<p>Douglas Lane &amp; Associates LLC lowered its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 1.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,444,268 shares of the company's stock after selling 68,407 shares during the period. Douglas Lane &amp; Associates LLC owned 0.69% of Elanco Animal Health worth $69,368,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>道格拉斯·莱恩与合伙公司在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第三季度将其在艾朗克动物健康公司（NYSE:ELAN - 免费报告）的股份减少了 1.9%。该基金在此期间出售了 68,407 股后，持有 3,444,268 股该公司的股票。道格拉斯·莱恩与合伙公司在其最近向证券交易委员会（SEC）提交的文件中拥有艾朗克动物健康 0.69% 的股份，价值 69,368,000 美元。</p>
</div><p>Get <strong>Elanco Animal Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>艾朗克动物健康</strong> 的提醒：</p>
</div><ul>
<li>Bullish or Bearish? Vetting Animal Health Care Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>看涨还是看跌？评估动物健康护理股票</li>
</ul>
</div><p>Other hedge funds and other institutional investors have also recently modified their holdings of the company. First Horizon Advisors Inc. increased its holdings in Elanco Animal Health by 184.3% in the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company's stock valued at $53,000 after acquiring an additional 2,414 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of Elanco Animal Health by 261.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company's stock valued at $58,000 after purchasing an additional 2,922 shares in the last quarter. Geneos Wealth Management Inc. increased its holdings in shares of Elanco Animal Health by 53.7% in the second quarter. Geneos Wealth Management Inc. now owns 5,954 shares of the company's stock worth $85,000 after purchasing an additional 2,080 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Elanco Animal Health by 26.4% in the second quarter. EverSource Wealth Advisors LLC now owns 6,379 shares of the company's stock worth $91,000 after purchasing an additional 1,332 shares during the last quarter. Finally, Parallel Advisors LLC lifted its position in shares of Elanco Animal Health by 66.6% in the second quarter. Parallel Advisors LLC now owns 6,432 shares of the company's stock worth $92,000 after buying an additional 2,572 shares in the last quarter. Institutional investors own 97.48% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也调整了对该公司的持股。第一地平线顾问公司在第二季度将其在艾朗克动物健康的持股增加了 184.3%。第一地平线顾问公司现在拥有 3,724 股该公司的股票，价值 53,000 美元，此前在上个季度增持了 2,414 股。凯通国际资产管理有限公司在第二季度将其在艾朗克动物健康的持股增加了 261.6%。凯通国际资产管理有限公司现在拥有 4,039 股该公司的股票，价值 58,000 美元，此前在上个季度增持了 2,922 股。基诺斯财富管理公司在第二季度将其在艾朗克动物健康的持股增加了 53.7%。基诺斯财富管理公司现在拥有 5,954 股该公司的股票，价值 85,000 美元，此前在上个季度增持了 2,080 股。EverSource 财富顾问公司在第二季度将其在艾朗克动物健康的持股增加了 26.4%。EverSource 财富顾问公司现在拥有 6,379 股该公司的股票，价值 91,000 美元，此前在上个季度增持了 1,332 股。最后，平行顾问公司在第二季度将其在艾朗克动物健康的持股增加了 66.6%。平行顾问公司现在拥有 6,432 股该公司的股票，价值 92,000 美元，此前在上个季度增持了 2,572 股。机构投资者持有该公司 97.48% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of analysts have issued reports on the company. Barclays began coverage on Elanco Animal Health in a research note on Tuesday, December 9th. They issued an &#34;overweight&#34; rating and a $30.00 price objective on the stock. Morgan Stanley boosted their price target on shares of Elanco Animal Health from $18.00 to $22.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Thursday. Zacks Research lowered shares of Elanco Animal Health from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, November 6th. UBS Group lifted their price objective on shares of Elanco Animal Health from $25.00 to $27.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, November 6th. Finally, Argus upgraded shares of Elanco Animal Health from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $25.00 target price on the stock in a research report on Wednesday, November 19th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $23.78.</p>
<div class="lb-trans"><p>多位分析师对该公司发布了报告。巴克莱在 12 月 9 日的研究报告中开始覆盖艾朗克动物健康。他们对该股票给予了 “增持” 评级，并设定了 30.00 美元的目标价。摩根士丹利在周四将艾朗克动物健康的目标价从 18.00 美元上调至 22.00 美元，并给予该股票 “持平” 评级。扎克斯研究在 11 月 6 日的研究报告中将艾朗克动物健康的评级从 “强力买入” 下调至 “持有”。瑞银集团在 11 月 6 日的研究报告中将艾朗克动物健康的目标价从 25.00 美元上调至 27.00 美元，并给予该股票 “买入” 评级。最后，阿古斯在 11 月 19 日的研究报告中将艾朗克动物健康的评级从 “持有” 上调至 “买入”，并设定了 25.00 美元的目标价。两位投资分析师对该股票给予了强力买入评级，七位给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 23.78 美元。</p>
</div><ul>
<li>Zoetis Declares New Dividend, Hinting At Undervaluation</li>
</ul>
<div class="lb-trans"><ul>
<li>Zoetis 宣布新股息，暗示被低估</li>
</ul>
</div><p><strong>Read Our Latest Research Report on Elanco Animal Health</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于艾朗克动物健康的最新研究报告</strong></p>
</div><h2>Elanco Animal Health Stock Performance</h2>
<div class="lb-trans"><h2>艾朗克动物健康股票表现</h2>
</div><p>Elanco Animal Health stock opened at $22.28 on Friday. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $23.70. The company's 50-day moving average is $21.92 and its 200 day moving average is $18.37. The firm has a market capitalization of $11.07 billion, a P/E ratio of 371.40, a price-to-earnings-growth ratio of 3.41 and a beta of 1.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23.</p>
<div class="lb-trans"><p>艾朗克动物健康的股票在周五开盘价为 22.28 美元。艾朗克动物健康公司的一年最低价为 8.02 美元，一年最高价为 23.70 美元。该公司的 50 日移动平均线为 21.92 美元，200 日移动平均线为 18.37 美元。该公司的市值为 110.7 亿美元，市盈率为 371.40，市盈增长比率为 3.41，贝塔值为 1.86。该公司的债务与股本比率为 0.59，流动比率为 2.40，速动比率为 1.23。</p>
</div><ul>
<li>2 Contrarian Stock Picks With Major Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只具有重大上涨潜力的逆向股票推荐</li>
</ul>
</div><p>Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the prior year, the business posted $0.13 earnings per share. The company's revenue for the quarter was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Research analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.</p>
<div class="lb-trans"><p>艾朗克动物健康（NYSE:ELAN - 获取免费报告）在 11 月 5 日星期三发布了季度财报。该公司报告每股收益为 0.19 美元，超出市场共识预期的 0.13 美元，超出幅度为 0.06 美元。艾朗克动物健康的股本回报率为 7.41%，净利润率为 0.78%。该公司在本季度的收入为 11.4 亿美元，而市场共识预期为 10.9 亿美元。在去年同期，该公司每股收益为 0.13 美元。该公司本季度的收入同比增长 10.4%。艾朗克动物健康已将其 2025 财年的指导目标设定为每股收益 0.910-0.940 美元，并将其 2025 年第四季度的指导目标设定为每股收益 0.090-0.120 美元。研究分析师预测艾朗克动物健康公司本年度将发布 0.91 美元的每股收益。</p>
</div><h2>Insider Activity at Elanco Animal Health</h2>
<div class="lb-trans"><h2>艾朗克动物健康的内部活动</h2>
</div><p>In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the company's stock in a transaction dated Friday, December 12th. The shares were purchased at an average cost of $21.30 per share, for a total transaction of $213,000.00. Following the completion of the purchase, the director owned 131,773 shares in the company, valued at approximately $2,806,764.90. This trade represents a 8.21% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Rajeev A. Modi acquired 4,500 shares of the business's stock in a transaction that occurred on Thursday, December 11th. The shares were acquired at an average cost of $21.33 per share, for a total transaction of $95,985.00. Following the completion of the acquisition, the insider owned 123,082 shares of the company's stock, valued at $2,625,339.06. This trade represents a 3.79% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 43,450 shares of company stock valued at $937,883 over the last ninety days. Company insiders own 0.89% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Elanco Animal Health 的新闻中，董事 Lawrence Erik Kurzius 于 12 月 12 日（星期五）购买了公司 10,000 股股票。每股的平均购买成本为 21.30 美元，总交易额为 213,000.00 美元。完成购买后，该董事在公司拥有 131,773 股股票，估值约为 2,806,764.90 美元。这笔交易代表了他们持股比例的 8.21% 的增长。该交易已在向 SEC 提交的文件中披露，可以通过此链接访问。此外，内部人士 Rajeev A. Modi 于 12 月 11 日（星期四）购买了公司 4,500 股股票。每股的平均购买成本为 21.33 美元，总交易额为 95,985.00 美元。完成收购后，该内部人士拥有 123,082 股公司的股票，估值为 2,625,339.06 美元。这笔交易代表了他们持股比例的 3.79% 的增长。有关此次购买的更多细节可在官方 SEC 披露中找到。在过去的九十天里，内部人士共购买了 43,450 股公司股票，价值为 937,883 美元。公司内部人士持有公司股票的 0.89%。</p>
</div><h2>Elanco Animal Health Company Profile</h2>
<div class="lb-trans"><h2>Elanco Animal Health 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.</p>
<div class="lb-trans"><p>Elanco Animal Health Inc 是一家全球领先的动物健康公司，致力于改善食品和伴侣动物的福祉。该公司开发、生产和销售一系列产品，包括寄生虫药、疫苗、抗生素和饲料添加剂，旨在预防和治疗家畜和宠物的疾病。Elanco 的产品组合涵盖了食品生产动物（如牛、猪、家禽和水产养殖）和伴侣动物，提供支持寄生虫控制、疼痛管理和传染病预防的产品。</p>
</div><p>Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.</p>
<div class="lb-trans"><p>Elanco 最初成立于 20 世纪中期，作为礼来公司（Eli Lilly and Company）的动物健康部门，并于 2018 年分拆为一家独立的上市公司。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Elanco Animal Health</li>
<li>How Technical Indicators Can Help You Find Oversold Stocks</li>
<li>These 3 Banks Are Rallying Into Year-End, But Will It Continue?</li>
<li>What is a Death Cross in Stocks?</li>
<li>3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&amp;P 500</li>
<li>3 REITs to Buy and Hold for the Long Term</li>
<li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Elanco Animal Health</li>
<li>技术指标如何帮助你找到被低估的股票</li>
<li>这三家银行在年末上涨，但这种趋势会持续吗？</li>
<li>股票中的死亡交叉是什么？</li>
<li>这三只飙升的股票刚刚获得标准普尔 500 的最终认可</li>
<li>三只 REIT 值得长期持有</li>
<li>这只 ETF 在美联储降息后获得了重大助力</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMQU4" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ELAN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Elanco Animal Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Elanco Animal Health 吗？</h2>
</div><p>Before you consider Elanco Animal Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Elanco Animal Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elanco Animal Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Elanco Animal Health 并不在名单上。</p>
</div><p>While Elanco Animal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Elanco Animal Health 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Douglas Lane & Associates LLC 减持了 Elanco Animal Health Incorporated（$ELAN）的股份